Benzinga

Benzinga

Benzinga

viernes, agosto 21

Lipocine Inc

LPCNNASDAQ
Trade with Public
Trade with Public
$2.09
0.041.95%
al cierre: Aug 19, 5:00 PM EST
$2.06
0.010.49%
Premercado: 7:00 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Lipocine Financials

Lipocine (LPCN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Lipocine Q2 EPS $(0.32) Beats $(0.43) Estimate, Sales $190.099K Beat $156.500K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 21.95 percent increase over losses of $(0.41) per share from the
Benzinga Newsdesk

PRO
CORRECTION: Lipocine Q1 EPS $(0.54) Misses $(0.48) Estimate, Sales $119.397K Miss $162.500K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 54.29 percent decrease over losses of $(0.35) per share from the
Benzinga Newsdesk

PRO
Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.55) by 8.26 percent. This is a 34.09 percent decrease over losses of $(0.44) per share from the
Benzinga Newsdesk

PRO
CORRECTION: Lipocine Q2 EPS $(0.41) Misses $(0.40) Estimate, Sales $622.849K Beat $229.000K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.40) by 2.5 percent. This is a 26.79 percent increase over losses of $(0.56) per share from the same
Benzinga Newsdesk

PRO
Lipocine Q1 EPS $(0.35) Beats $(0.41) Estimate, Sales $93.86K Miss $370.00K Estimate

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14.63 percent. This is a 153.03 percent decrease over earnings of $0.66 per share from the
Benzinga Newsdesk

PRO
Lipocine FY24 Sales $11.198M Beat $10.321M Estimate

Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved